This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Mar;21(3):320-322.

doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3.

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

Sabine Schmid¹, Martin Früh², Solange Peters³

Affiliations

Affiliations

¹ Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology Lung Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.
² Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology, University of Berne, Berne, Switzerland.
³ Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, CH-1011 Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.

PMID: 32027845
DOI: 10.1016/S1470-2045(19)30859-9

Comment

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

Sabine Schmid et al. Lancet Oncol. 2020 Mar.

. 2020 Mar;21(3):320-322.

doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3.

Authors

Sabine Schmid¹, Martin Früh², Solange Peters³

Affiliations

¹ Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology Lung Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.
² Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology, University of Berne, Berne, Switzerland.
³ Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, CH-1011 Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.

PMID: 32027845
DOI: 10.1016/S1470-2045(19)30859-9

No abstract available

PubMed Disclaimer

Comment on

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Sequist LV, et al. Lancet Oncol. 2020 Mar;21(3):373-386. doi: 10.1016/S1470-2045(19)30785-5. Epub 2020 Feb 3. Lancet Oncol. 2020. PMID: 32027846 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal